Results 261 to 270 of about 377,245 (300)
Some of the next articles are maybe not open access.
Journal of Neuroscience Nursing, 2007
More than 700,000 people have a stroke each year in the United States. A diagnosis of stroke formerly elicited a nihilistic approach, but this has substantially changed in the last decade. Currently, time is brain, and it is important for all disciplines to work together to initiate acute stroke protocols in the emergency department and identify ...
Janice L, Hinkle, Mary McKenna, Guanci
openaire +2 more sources
More than 700,000 people have a stroke each year in the United States. A diagnosis of stroke formerly elicited a nihilistic approach, but this has substantially changed in the last decade. Currently, time is brain, and it is important for all disciplines to work together to initiate acute stroke protocols in the emergency department and identify ...
Janice L, Hinkle, Mary McKenna, Guanci
openaire +2 more sources
Acute Ischemic Stroke Management
Thrombosis Research, 2000The use of thrombolytic therapy represents one of many recent developments in the management of acute ischemic stroke. The development of stroke teams and protocols has been driven by these new demands for an urgent response to ischemic stroke. The short time window of 3 hours for therapy with intravenous recombinant tissue plasminogen activator ...
R P, Atkinson, C, DeLemos
openaire +2 more sources
Neurologic Clinics, 2000
Acute ischemic stroke is a medical emergency that requires rapid evaluation and treatment. Prehospital and emergency department care can be streamlined to meet those goals. Intravenous rt-PA therapy improves outcome in selected patients with ischemic stroke if given within 3 hours of stroke onset, but offers no benefit beyond that time window.
S L, Hickenbottom, W G, Barsan
openaire +2 more sources
Acute ischemic stroke is a medical emergency that requires rapid evaluation and treatment. Prehospital and emergency department care can be streamlined to meet those goals. Intravenous rt-PA therapy improves outcome in selected patients with ischemic stroke if given within 3 hours of stroke onset, but offers no benefit beyond that time window.
S L, Hickenbottom, W G, Barsan
openaire +2 more sources
Expert Review of Cardiovascular Therapy, 2010
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up ...
Henninger, Nils +2 more
openaire +3 more sources
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up ...
Henninger, Nils +2 more
openaire +3 more sources
Thrombolysis for Acute Ischemic Stroke
Current Topics in Medicinal Chemistry, 2009In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which
Uyttenboogaart, M +2 more
openaire +3 more sources
2016
Acute ischemic stroke is common and often treatable, but treatment requires reliable information on the state of the brain that may be provided by modern neuroimaging. Critical information includes: the presence of hemorrhage; the site of arterial occlusion; the size of the early infarct "core"; and the size of underperfused, potentially threatened ...
R Gilberto, González, Lee H, Schwamm
openaire +2 more sources
Acute ischemic stroke is common and often treatable, but treatment requires reliable information on the state of the brain that may be provided by modern neuroimaging. Critical information includes: the presence of hemorrhage; the site of arterial occlusion; the size of the early infarct "core"; and the size of underperfused, potentially threatened ...
R Gilberto, González, Lee H, Schwamm
openaire +2 more sources
Thrombolysis in Acute Ischemic Stroke
1996Thrombolysis is an attractive but potentially dangerous they for cerebral ischemia: it is capable of dissolving an arterial thrombus, but can also transform a pale infarct into a hematoma and/or may cause severe oedema and herniation. The safety and efficacy of the treatment critically depend on the timing of intervention ad on patient selection.
FIESCHI, Cesare +8 more
openaire +3 more sources
2007
In the Clinical Practice article by van der Worp and van Gijn (Aug. 9 issue),1 the question of the age at which a patient could be selected for treatment with intravenous thrombolysis warrants further attention. According to the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST) selection criteria,2 this treatment cannot be ...
CHITI, ALBERTO +2 more
openaire +3 more sources
In the Clinical Practice article by van der Worp and van Gijn (Aug. 9 issue),1 the question of the age at which a patient could be selected for treatment with intravenous thrombolysis warrants further attention. According to the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST) selection criteria,2 this treatment cannot be ...
CHITI, ALBERTO +2 more
openaire +3 more sources
2017
The primary focus for the initial treatment of acute ischemic stroke is determining whether a patient who presents with acute neurological deficits is a candidate for intravenous (IV) thrombolytic therapy. Within the last two decades, the use of IV alteplase (tPA) for acute ischemic stroke together with the establishment of stroke systems of care has ...
Karin Nyström, Joseph Schindler
openaire +1 more source
The primary focus for the initial treatment of acute ischemic stroke is determining whether a patient who presents with acute neurological deficits is a candidate for intravenous (IV) thrombolytic therapy. Within the last two decades, the use of IV alteplase (tPA) for acute ischemic stroke together with the establishment of stroke systems of care has ...
Karin Nyström, Joseph Schindler
openaire +1 more source